{"nctId":"NCT00395135","briefTitle":"BLOOM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management","startDateStruct":{"date":"2006-11"},"conditions":["Obesity"],"count":3182,"armGroups":[{"label":"Lorcaserin 10 mg BID","type":"EXPERIMENTAL","interventionNames":["Drug: Lorcaserin 10 mg BID"]},{"label":"Matching Placebo BID","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Matching Placebo BID"]}],"interventions":[{"name":"Lorcaserin 10 mg BID","otherNames":["APD356"]},{"name":"Matching Placebo BID","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Obese adults with a BMI 30 to 45 kg/m2 or overweight adults with a BMI 27 to 29.9 kg/m2 and at least one obesity-related comorbidity (hypertension, dyslipidemia, cardiovascular disease, glucose intolerance, sleep apnea)\n* Ability to complete a 2 year study\n\nExclusion Criteria:\n\n* Diabetes\n* Pregnancy\n* History of heart valve disease\n* Serious or unstable current or past medical conditions","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Year 1: Co-Primary Endpoint- Proportion (%) of Patients Achieving > or = 5% Weight Loss From Baseline to Week 52","description":"The proportion of patients with a reduction from baseline body weight of 5% or more at the end of year 1.\n\nOther co-primary endpoints are change from baseline in body weight (kg) at year 1 and the proportion of patients achieving â‰¥ 10% reduction in body weight at year 1.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.5","spread":null},{"groupId":"OG001","value":"20.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Year 2: Proportion (%) of Patients Maintaining > or = 5% Weight Loss at Week 104","description":"The proportion of patients with a reduction from baseline body weight of 5% or more at the end of year 1 and who maintained this reduction during year 2.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.9","spread":null},{"groupId":"OG001","value":"50.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Year 1: Percent Change in Body Weight From Baseline to Week 52","description":"Year 1: The % change in body weight (kg) from baseline to week 52.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.87","spread":"0.18"},{"groupId":"OG001","value":"-2.20","spread":"0.18"}]}]}]},{"type":"SECONDARY","title":"Year 2: Percent Change in Body Weight From Week 52 to Week 104","description":"Year 2: The % change in body weight (kg) from week 52 to week 104.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.79","spread":"0.23"},{"groupId":"OG001","value":"5.38","spread":"0.31"},{"groupId":"OG002","value":"1.15","spread":"0.22"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":38,"n":1593},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Headache","Sinusitis","Urinary tract infection"]}}}